The Novartis pharmaceutical company will use artificial intelligence of IBM for cancer therapy of mammary glands

On June 5, 2017 it became known of intentions of large Swiss pharmaceutical company Novartis to use artificial intelligence technologies of IBM for search of methods of cancer therapy of a mammary gland.

As reported by Reuters, within the agreement Novartis will work with the IBM Watson Health platform to study ways of use of these patients and mechanisms of advanced analytics for the purpose of obtaining information on possible results of treatment of oncological diseases of mammary glands.

The Novartis pharmaceutical company will use artificial intelligence of IBM for cancer therapy of mammary glands

Thanks to cooperation with IBM Watson Health we in the real world will use data on a breast cancer and cognitive calculations for finding solutions which can help doctors to select optimal therapy for patients or will make recommendations about clinical practice" — the head of department of oncology of Novartis Bruno Strigini says. — We hope that partnership will also allow to find effective methods of treatment which can be applied not only at a breast cancer.

IBM offers the tools created based on Watson which help oncologists to make the correct decisions on sick crayfish and facilitate search of compliance of these patients to results of clinical trials. Novartis sells four medicine for patients with cancer of a mammary gland.

At a meeting of the American society of clinical oncology (ASCO) in May, 2017 results of the researches indicating that the IBM Watson supercomputer appoints the cancer patient approximately the same course of treatment, as the doctor were published. So, in the Manipalsky complex oncological center in Bangalore (India) counted that the artificial intelligence of IBM makes recommendations about cancer therapy of lungs, thick and a rectum with a medical accuracy of 96%, 81% and 93% respectively. Oncologists of the International hospital in Bumrungrada (Bangkok, Thailand) announced a 83 percent indicator.^[1]

Notes